# Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

> **NCT05077215** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Evergreen Therapeutics, Inc.** · enrollment: 450 (estimated)

## Conditions studied

- Advanced Endometrial Cancer

## Interventions

- **DRUG:** EG-007
- **DRUG:** Pembrolizumab 100 mg/ 4 ml (25 mg/ml) Injection
- **DRUG:** Lenvatinib Capsules

## Key facts

- **NCT ID:** NCT05077215
- **Lead sponsor:** Evergreen Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2027-12
- **Final completion:** 2027-12
- **Target enrollment:** 450 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05077215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05077215, "Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT05077215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*